GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound 18 [PMID: 22458531] | PG-545 | PG545
Compound class:
Synthetic organic
Comment: Pixatimod (PG545) is a heparan sulphate mimetic that acts as an inhibitor of the heparanase enzyme [3-4]. Structurally it is a cholestanol-conjugated sulfated oligosaccharide.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
A dose-finding Phase 1 study in 4 subjects, that began in 2010, was terminated due to patients developing unexpected injection site reactions (NCT01252095). However, pixatimod (PG545) has now completed a separate safety and tolerability Phase 1 clinical study (NCT02042781) in patients with advanced solid tumours. Study resuts indicate evidence of immune cell stimulation and a level of disease control in some patients [2]. These results support the proposed mechanism of action of PG545. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01252095 | Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours | Phase 1 Interventional | Zucero Pty Ltd | ||
NCT02042781 | Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours | Phase 1 Interventional | Zucero Pty Ltd |